Sign In
Buy TLSA
$1.03
+0.0600 (+6.19%)
At Close: Jul 31, 2026
Shares in Tiziana Life Sciences plc (NASDAQ:TLSA, LON:TILS) shot up 20% after it announced the US regulator has approved the use of its nasally administered monoclonal antibody to treat a person with
TLSA Stock Price Increased Over 10% Pre-Market: Why It Happened
08:46am, Tuesday, 30'th Mar 2021
The stock price of Tiziana Life Sciences plc (NASDAQ: TLSA) has increased by over 10% pre-market. This is why it happened.
Tiziana Life Sciences plc: Accustem Update
07:35am, Tuesday, 30'th Mar 2021
NEW YORK and LONDON, March 30, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences. (NASDAQ: TLSA; LSE: TILS), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and inf
Tiziana Life Sciences plans phase II trials of nasal antibody treatment in COVID-19 patients
03:15am, Tuesday, 30'th Mar 2021
Tiziana Life Sciences PLC (NASDAQ:TLSA, LON:TILS) is taking its nasally-administered monoclonal antibody (mAB) into phase II clinical trials in people with moderate to severe Coronavirus (COVID-19). T
Tiziana Life Sciences planning phase II clinical trial of monoclonal antibody treatment in patients with moderate to severe COVID-19
02:48am, Tuesday, 30'th Mar 2021
Tiziana Life Sciences PLC (NASDAQ:TLSA, LON:TILS) is taking its nasally-administered monoclonal antibody (mAB) into phase II clinical trials in people with moderate to severe COVID-19. This follows an
NEW YORK and LONDON, March 29, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences (NASDAQ: TLSA; LSE: TILS), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infe
NEW YORK and LONDON, March 29, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences. (NASDAQ: TLSA; LSE: TILS), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and inf
Tiziana Life Sciences Interview to Air on Bloomberg Television US on The RedChip Money Report
02:00am, Friday, 26'th Feb 2021
NEW YORK and LONDON, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences (NASDAQ: TLSA; LSE: TILS), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infe
Tiziana Life Sciences to present at BIO CEO & Investor online conference
11:02am, Tuesday, 16'th Feb 2021
Tiziana Life Sciences PLC (LON:TILS, NASDAQ:TLSA) said it is presenting at the BIO CEO & Investor Digital Conference. The conference starts today and runs until Thursday.
Proactive news headlines: Iconic Labs, Silence Therapeutics, Chaarat Gold, Tiziana Life Sciences.
02:54pm, Sunday, 07'th Feb 2021
Iconic Labs PLC (LON:ICON), a multidivisional new media and technology business, announced that it has appointed Sarah Dees as its chief executive officer and an executive director with immediate effe
Tiziana Life Sciences plc ("Tiziana" or the "Company") - Appointment of Director
02:00am, Friday, 05'th Feb 2021
NEW YORK and LONDON, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ: TLSA / LSE: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for
Tiziana (TLSA) Posts Positive Data on Nasal COVID-19 Antibody
11:22am, Wednesday, 03'rd Feb 2021
Tiziana (TLSA) reports positive data from a study investigating its anti-CD3 human monoclonal antibody, foralumab (nasally administered) for treating COVID-19 patients in Brazil. Shares up.
Tiziana Life Sciences CEO Discusses COVID-19 Trial Data in Exclusive Interview
02:00am, Wednesday, 03'rd Feb 2021
NEW YORK and LONDON, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ:TLSA/LSE:TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for on
TLSA Stock Price Increases Over 40% Pre-Market: Why It Happened
06:19am, Tuesday, 02'nd Feb 2021
The stock price of Tiziana Life Sciences (NASDAQ: TLSA) increased by over 40% pre-market as of 6:05 AM ET. This is why it happened.
NEW YORK and LONDON, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / LSE: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeu
